Lifeline drug access for rare fat disorder patients
NCT ID NCT02262806
Summary
This study provides continued access to the drug metreleptin for people with partial lipodystrophy, a rare condition that causes severe diabetes and high blood fats. It is for patients who have already benefited from the drug in past NIH studies but cannot get it through regular channels. The goal is to help control their metabolic problems long-term and gather more safety and effectiveness data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.